581 related articles for article (PubMed ID: 29470683)
41. Reclassification of Mongolian Diffuse Gliomas According to the Revised 2016 World Health Organization Central Nervous System Tumor Classification.
Ochirjav E; Enkhbat B; Baldandorj T; Choe G
J Pathol Transl Med; 2019 Sep; 53(5):298-307. PubMed ID: 31370384
[TBL] [Abstract][Full Text] [Related]
42. Neuroimaging-Based Classification Algorithm for Predicting 1p/19q-Codeletion Status in
Batchala PP; Muttikkal TJE; Donahue JH; Patrie JT; Schiff D; Fadul CE; Mrachek EK; Lopes MB; Jain R; Patel SH
AJNR Am J Neuroradiol; 2019 Mar; 40(3):426-432. PubMed ID: 30705071
[TBL] [Abstract][Full Text] [Related]
43. Individualized discrimination of tumor progression from treatment-related changes in different types of adult-type diffuse gliomas using [
Chen Q; Wang K; Ren X; Zhao X; Chen Q; Fan D; Zhang S; Li X; Ai L
J Neurooncol; 2023 Dec; 165(3):547-559. PubMed ID: 38095773
[TBL] [Abstract][Full Text] [Related]
44. Static and dynamic
Verger A; Stoffels G; Bauer EK; Lohmann P; Blau T; Fink GR; Neumaier B; Shah NJ; Langen KJ; Galldiks N
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):443-451. PubMed ID: 29043400
[TBL] [Abstract][Full Text] [Related]
45. High-grade gliomas with isocitrate dehydrogenase wild-type and 1p/19q codeleted: Atypical molecular phenotype and current challenges in molecular diagnosis.
Zheng L; Zhang M; Hou J; Gong J; Nie L; Chen X; Zhou Q; Chen N
Neuropathology; 2020 Dec; 40(6):599-605. PubMed ID: 32761642
[TBL] [Abstract][Full Text] [Related]
46. Molecular classification of adult diffuse gliomas: conflicting IDH1/IDH2, ATRX, and 1p/19q results.
Ballester LY; Huse JT; Tang G; Fuller GN
Hum Pathol; 2017 Nov; 69():15-22. PubMed ID: 28549927
[TBL] [Abstract][Full Text] [Related]
47. Reclassification of 400 consecutive glioma cases based on the revised 2016WHO classification.
Akagi Y; Yoshimoto K; Hata N; Kuga D; Hatae R; Amemiya T; Sangatsuda Y; Suzuki SO; Iwaki T; Mizoguchi M; Iihara K
Brain Tumor Pathol; 2018 Apr; 35(2):81-89. PubMed ID: 29569163
[TBL] [Abstract][Full Text] [Related]
48. The 2016 revision of the WHO Classification of Central Nervous System Tumours: retrospective application to a cohort of diffuse gliomas.
Rogers TW; Toor G; Drummond K; Love C; Field K; Asher R; Tsui A; Buckland M; Gonzales M
J Neurooncol; 2018 Mar; 137(1):181-189. PubMed ID: 29218432
[TBL] [Abstract][Full Text] [Related]
49. Clinical impact of revisions to the WHO classification of diffuse gliomas and associated future problems.
Sonoda Y
Int J Clin Oncol; 2020 Jun; 25(6):1004-1009. PubMed ID: 32020379
[TBL] [Abstract][Full Text] [Related]
50. H3K27me3 immunostaining is diagnostic and prognostic in diffuse gliomas with oligodendroglial or mixed oligoastrocytic morphology.
Ammendola S; Caldonazzi N; Simbolo M; Piredda ML; Brunelli M; Poliani PL; Pinna G; Sala F; Ghimenton C; Scarpa A; Barresi V
Virchows Arch; 2021 Nov; 479(5):987-996. PubMed ID: 34165590
[TBL] [Abstract][Full Text] [Related]
51. Diagnostic Performance of [
Nakajo K; Uda T; Kawashima T; Terakawa Y; Ishibashi K; Tsuyuguchi N; Tanoue Y; Nagahama A; Uda H; Koh S; Sasaki T; Ohata K; Kanemura Y; Goto T
World Neurosurg; 2021 Apr; 148():e471-e481. PubMed ID: 33444827
[TBL] [Abstract][Full Text] [Related]
52. Somatostatin receptor 2A in gliomas: Association with oligodendrogliomas and favourable outcome.
Kiviniemi A; Gardberg M; Kivinen K; Posti JP; Vuorinen V; Sipilä J; Rahi M; Sankinen M; Minn H
Oncotarget; 2017 Jul; 8(30):49123-49132. PubMed ID: 28467778
[TBL] [Abstract][Full Text] [Related]
53. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
[TBL] [Abstract][Full Text] [Related]
54. Static
Song S; Wang L; Yang H; Shan Y; Cheng Y; Xu L; Dong C; Zhao G; Lu J
Eur Radiol; 2021 Jun; 31(6):4087-4096. PubMed ID: 33211141
[TBL] [Abstract][Full Text] [Related]
55. TERT promoter mutations contribute to subset prognostication of lower-grade gliomas.
Chan AK; Yao Y; Zhang Z; Chung NY; Liu JS; Li KK; Shi Z; Chan DT; Poon WS; Zhou L; Ng HK
Mod Pathol; 2015 Feb; 28(2):177-86. PubMed ID: 25081751
[TBL] [Abstract][Full Text] [Related]
56. A simple algorithmic approach using histology and immunohistochemistry for the current classification of adult diffuse glioma in a resource-limited set-up.
Rajeswarie RT; Rao S; Nandeesh BN; Yasha TC; Santosh V
J Clin Pathol; 2018 Apr; 71(4):323-329. PubMed ID: 28801347
[TBL] [Abstract][Full Text] [Related]
57. Molecular biomarkers and integrated pathological diagnosis in the reclassification of gliomas.
Ruiz MF; Gennaro MV; Bastone LC; Godoy AR; Torruella M; Perez GR
Mol Clin Oncol; 2021 Aug; 15(2):150. PubMed ID: 34141429
[TBL] [Abstract][Full Text] [Related]
58. Estimation of the occurrence rates of
Cho U; Yang SH; Yoo C
J Int Med Res; 2021 Jun; 49(6):3000605211019258. PubMed ID: 34162262
[TBL] [Abstract][Full Text] [Related]
59. Molecular profile of tumors with oligodendroglial morphology: Clinical relevance.
Geevar T; Pai R; Chacko G; Malepathi K; Patel B; John J; Chacko AG; Balakrishnan R; John S
Neurol India; 2018; 66(6):1726-1731. PubMed ID: 30504574
[TBL] [Abstract][Full Text] [Related]
60. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
